Literature DB >> 19179187

Treatment for patients with unknown primary cancer and favorable prognostic factors.

John D Hainsworth1, Karim Fizazi.   

Abstract

Patients with carcinoma of unknown primary site are heterogeneous with respect to clinical and pathologic features. Within this diverse group, specific clinical and/or pathologic features can be used to define several subsets with favorable prognoses. Specific subsets include women with peritoneal carcinomatosis, women with isolated axillary lymph node metastases, adenocarcinoma presenting as a single metastatic lesion, young men with features of extragonadal germ cell tumor, squamous carcinoma involving cervical or inguinal lymph nodes, and neuroendocrine carcinoma. Prospective identification of patients in these favorable subgroups allows the most effective treatment to be selected. This review summarizes current recommendations for the evaluation and treatment of patients in each of these favorable prognostic subsets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179187     DOI: 10.1053/j.seminoncol.2008.10.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  20 in total

Review 1.  Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.

Authors:  F Anthony Greco
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 2.  Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.

Authors:  Kyung Won Kim; Katherine M Krajewski; Jyothi P Jagannathan; Mizuki Nishino; Atul B Shinagare; Jason L Hornick; Nikhil H Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

Review 3.  Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines.

Authors:  M B Taylor; N R Bromham; S E Arnold
Journal:  Br J Radiol       Date:  2012-02-28       Impact factor: 3.039

Review 4.  Carcinomas of an unknown primary origin--diagnosis and treatment.

Authors:  Christophe Massard; Yohann Loriot; Karim Fizazi
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

5.  A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site.

Authors:  Anne Kirstine H Møller; Annika Loft; Anne K Berthelsen; Karen D Pedersen; Jesper Graff; Charlotte B Christensen; Junia C Costa; Lene T Skovgaard; Katharina Perell; Bodil L Petersen; Gedske Daugaard
Journal:  Oncologist       Date:  2012-06-18

6.  Clinical Outcomes in Patients with Cancer of Unknown Primary Site Treated By Gastrointestinal Oncologists.

Authors:  Sakiko Yamane; Chikatoshi Katada; Satoshi Tanabe; Mizutomo Azuma; Kenji Ishido; Takafumi Yano; Takuya Wada; Akinori Watanabe; Natsuko Kawanishi; Yasuaki Furue; Yuki Kondo; Shouko Komori; Hiromichi Ishiyama; Kazushige Hayakawa; Wasaburo Koizumi
Journal:  J Transl Int Med       Date:  2017-03-31

7.  Clinical presentation of carcinoma of unknown primary: 14 years of experience.

Authors:  Jun Ho Yi; Yoon La Choi; Su Jin Lee; Hee Kyung Ahn; Kyung Kee Baek; Taekyu Lim; Duk Joo Lee; Bo Ram Han; Ha Yeon Lee; Hyun Jung Jun; Jeeyun Lee; Yeon Hee Park
Journal:  Tumour Biol       Date:  2010-08-10

8.  Complete biologic response to taxane based chemotherapy confirmed by [F]FDG PET/CT and surgery in a cancer of unknown primary site.

Authors:  Jun-Eul Hwang; Ju-Young Yoon; Woo-Kyun Bae; Hyun-Jeong Shim; Ik-Joo Chung
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401

Review 9.  Molecular classification of cancers of unknown primary site.

Authors:  F Anthony Greco; Mark G Erlander
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

Review 10.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.